The U.S. infectious disease diagnostics market is projected to expand at a compound annual growth rate (CAGR) of 5.65% from 2025 to 2032, rising from USD 10.14 billion in 2024 to USD 15.48 billion by 2032. Several factors are driving this growth, including the increasing prevalence of infectious diseases, a broad array of available diagnostic tests, and the rising demand for point-of-care diagnostic solutions. Additionally, advancements in disease detection and monitoring technologies, alongside growing investments in improving disease model analysis, are key contributors to market expansion.
Understanding Infectious Disease Diagnostics
Infectious disease diagnostics involve identifying the pathogens responsible for infections, including bacteria, viruses, fungi, and parasites, in patients exhibiting clinical symptoms. These diagnostics play a crucial role in determining effective treatment strategies. Methods used in diagnosis include laboratory tests (blood, urine, or tissue analysis), imaging scans, and microbial cultivation and isolation. Advanced techniques such as antigen-based detection, genetic analysis, and immune response evaluation further enhance diagnostic accuracy, especially in resource-limited settings.
Despite strong growth prospects, market expansion may face challenges such as limited awareness of advanced diagnostic options, unclear regulatory frameworks, and suboptimal laboratory conditions affecting test accuracy. However, companies are actively engaging in product innovation and strategic business initiatives to overcome these hurdles.
In January 2025, Inflammatix, Inc. received FDA approval for its TriVerity Test System, a molecular diagnostic tool for assessing acute infections and sepsis. By analyzing immune responses, TriVerity differentiates between bacterial and viral infections while evaluating disease severity. Increased regulatory approvals for innovative diagnostic solutions are expected to further boost market confidence and growth.
Click â https://www.marketsandata.com/industry-reports/united-states-infectious-disease-diagnostics-market
Key Market Drivers
Rising Incidence of Infectious Diseases
The growing prevalence of infectious diseases continues to fuel demand for advanced diagnostic solutions. Global outbreaks such as COVID-19, SARS, and swine flu have underscored the need for robust diagnostic capabilities. Factors contributing to the spread of infections include environmental changes, increased human contact with new pathogens, and rising international travel. According to the World Health Organization (WHO), tuberculosis (TB) remains a leading infectious disease worldwide. The Centers for Disease Control and Prevention (CDC) reported an increase in TB cases in the U.S., from 8,332 in 2022 to 9,633 in 2023âa 15.6% rise. This growing disease burden highlights the need for enhanced diagnostic tools.
Increasing Demand for Point-of-Care Diagnostics
Factors such as urbanization, antibiotic resistance, and an aging population are contributing to the rise of infectious diseases in the U.S. The need for rapid diagnostic solutions is particularly evident in the fight against infections like HIV, where early detection is crucial for effective treatment. The CDC aims to reduce new HIV infections from 32,800 in 2022 to 9,300 by 2025 and further to 3,000 by 2030. The demand for quick, accessible testing is expected to drive growth in the point-of-care diagnostics (POCD) segment.
In response, both public and private entities are investing in new solutions. In April 2025, Cepheid Inc., a Danaher Corporation subsidiary, received WHO prequalification for its Xpert HIV-1 Qual XC test, which enhances HIV detection in blood samples.
Expanding Range of Diagnostic Tests
The market benefits from a wide array of diagnostic methods, including:
- Laboratory tests (blood, urine, and sputum analysis)
- Rapid diagnostic tests (quick identification of antigens and antibodies)
- Serological testing (detection of antibodies indicating prior infection)
- Polymerase Chain Reaction (PCR) tests (genetic identification of pathogens)
This diversity of diagnostic solutions is driving market expansion. Companies are introducing innovative testing kits to meet demand. In December 2024, Delve Bio, Inc. launched Delve Detect, a metagenomic test capable of analyzing cerebrospinal fluid (CSF) for over 68,000 pathogens, delivering results within 48 hours. This rapid, comprehensive diagnostic tool enhances the marketâs ability to address complex infectious diseases.
Leading Market Segment: Reagents, Kits, and Consumables
The reagents, kits, and consumables segment holds a significant share of the U.S. infectious disease diagnostics market. This dominance is attributed to the recurring need for these products and continuous advancements in molecular diagnostic techniques. The demand for reliable, easy-to-use testing solutions is driving repeated purchases.
For example, in December 2024, Panadea Diagnostics GmbH introduced Fc-receptor-based ELISA kits for detecting IgG antibodies against Zika, Dengue, and West Nile viruses, alongside a Dengue IgM detection kit. These new diagnostic tools underscore the importance of consumables in supporting accurate and efficient disease detection.
Future Outlook (2025-2032)
The future of the U.S. infectious disease diagnostics market looks promising, with increasing regulatory approvals paving the way for new diagnostic innovations. Organizations such as the Biomedical Advanced Research and Development Authority (BARDA) are actively supporting the development of medical solutions, leading to multiple FDA approvals. The Infectious Diseases Society of America (IDSA) is also advocating for new incentives and flexible regulations to drive research and development in infectious disease diagnostics.
As the regulatory landscape evolves, competition among key industry players is expected to intensify, leading to further innovations in diagnostic technology. The FDA continues to approve and grant emergency use authorizations for novel diagnostic devices, reinforcing the marketâs role in addressing emerging health threats.
Market Overview Report
The report âUnited States Infectious Disease Diagnostics Market Assessment, Opportunities, and Forecast (2018-2032F)â by Markets and Data provides an in-depth analysis of the market, covering industry dynamics, challenges, segmental growth, and key market players. It includes detailed market size projections, competitive intelligence, and business model evaluations, offering valuable insights into future market trends.
Latest reports-
https://www.marketsandata.com/industry-reports/agrivoltaics-market
https://www.marketsandata.com/industry-reports/acetic-acid-market
Contact
Mr. Vivek Gupta5741 Cleveland street,Suite 120, VA beach, VA, USA 23462Tel: +1 (757) 343â3258Email: info@marketsandata.comWebsite: https://www.marketsandata.com
